Meeting
2021 ASCO Annual Meeting
The sequence of chemotherapy and anti-PD-1 antibody influence the efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell cancer: A phase II study.
Authors
Lingdi Zhao
Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou City, China
Lingdi Zhao , Wenqun Xing , Yonghao Yang , Yong Zhang , Baozhen Ma , Xiaomin Fu , Guanghui Liang , Yiman Shang , Zibing WANG , Hongwei Lin , Quanli Gao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT 03985670
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4051)
DOI
10.1200/JCO.2021.39.15_suppl.4051
Abstract #
4051
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Preliminary results from a phase II study.
First Author: Xin-Gang Bi
Poster
2023 ASCO Annual Meeting
Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): A prospective, single-arm, phase II trial.
First Author: Jing Chen
Poster
2020 ASCO Virtual Scientific Program
SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.
First Author: Sacha Rothschild
